Tango Therapeutics (NASDAQ:TNGX - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $6.73 million for the quarter.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The firm had revenue of $4.12 million during the quarter, compared to analyst estimates of $7.84 million. On average, analysts expect Tango Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Tango Therapeutics Price Performance
NASDAQ TNGX traded up $0.02 on Friday, hitting $1.12. 467,242 shares of the stock were exchanged, compared to its average volume of 1,076,837. The company has a market capitalization of $121.08 million, a price-to-earnings ratio of -0.95 and a beta of 1.02. The company's 50-day moving average price is $1.51 and its two-hundred day moving average price is $2.71. Tango Therapeutics has a 52-week low of $1.03 and a 52-week high of $12.02.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a "buy" rating and set a $13.00 target price on shares of Tango Therapeutics in a research note on Monday, April 14th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Tango Therapeutics presently has a consensus rating of "Buy" and an average price target of $12.33.
Read Our Latest Analysis on Tango Therapeutics
About Tango Therapeutics
(
Get Free Report)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Featured Stories
Before you consider Tango Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.
While Tango Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
